|

TRI-611 Clinical Trials

1 actively recruiting trial across 1 location

No change since May 2026

Pipeline

Phase 1/2: 1

Top Sponsors

  • TRIANA Biomedicines, Inc.1

Indications

  • ALK-positive NSCLC1
  • ALK-Positive Lung Cancer1
  • ALK Positive Non-small Cell Lung Cancer1
  • Lung Cancer1
  • Cancer1

Aurora, Colorado1 trial

A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

University of Colorado Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.